Status: Recruiting
Assessment of AI Program 'DRISTi' as a Screening Tool
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.
Participants needed: 900
Trial details
Age: 21+Biological sex: AllType: ObservationalSponsor: Artelus AIUpdated: Dec 9, 2025Locations: 2
Eligibility criteria
Ability to sign and date the informed consent form [+6]
Persistent visual impairment in one or both eyes; [+10]